Merck on Monday said it was not providing long-time financial
forecasts as it assesses the impact of another failed study result for its Vytorin cholesterol fighter, which it produces with Schering Plough.
Merck has previously targeted double-digit compound annual earnings-per-share growth from 2005 through 2010, excluding certain items.
For the second quarter, the drugmaker said it earned $1.77 billion, or 82 cents per share, compared with $1.68 billion, or 77 cents per share, a year earlier. Analysts were expecting results of about 83 cents a share.
Excluding special items, the company earned 86 cents per share.